Previous 10 | Next 10 |
Ainos expands market for VELDONA® low-dose interferon treatment to animal care Products expected to launch in Taiwan in Q3 2023 SAN DIEGO, CA / ACCESSWIRE / March 21, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused o...
2023-03-14 10:46:46 ET The U.S. Bureau of Labor Statistics released the latest report on the Consumer Price Index for February 2023. CPI increased by 0.4 percent in February, following a 0.5 percent increase in January, on a seasonally adjusted basis. The all-items index increased by 6.0 pe...
2023-03-14 07:49:52 ET Ainos ( NASDAQ: AIMD ) signed an agreement with Taipei-listed Merdury Biopharmaceutical to explore a phase 3 trial of Veldona to treat oral warts in patients who are HIV-seropositive. Under the Memorandum of Understanding (MoU), the compani...
Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnerships SAN DIEGO, CA / ACCESSWIRE / March 14, 2023 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of no...
2023-03-13 17:45:56 ET Ainos ( NASDAQ: AIMD ) said Monday it entered into two convertible note purchase agreements, under which the company has issued and sold two convertible promissory notes worth US$3 million to certain investors. The notes will mature in two years followin...
SAN DIEGO, CA / ACCESSWIRE / March 13, 2023 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced t...
Ainos advances commercialization of its VELDONA® low-dose interferon treatment through strategic partnerships Ainos intends to begin clinical trials into VELDONA®'s potential veterinary applications in the first quarter of 2023 SAN DIEGO, CA / ACCESSWIRE / January 23, 2023 / A...
SAN DIEGO, CA / ACCESSWIRE / January 17, 2023 / Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, is pleased to ...
Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals PR Newswire VELDONA ® interferon-alpha formulation has shown potential as a treatment candid...
Amarillo Biosciences press release ( NASDAQ: AIMD ): Q3 GAAP EPS of -$0.51. Revenue of $1.75M (+386.1% Y/Y). For further details see: Amarillo Biosciences GAAP EPS of -$0.51, revenue of $1.75M
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States SRIVARU Holding Limited (SVMH) rose 94.8% to $0.2971 on volume of 77,516,058 shares NVIDIA Corporation (NVDA) fell 0.3% to $129.16 on volume of 39,120,242 shares Longeveron Inc. (LGVN) rose 27.0% to $3.415 on volume of 36,214,736 shar...
Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the way for next-gen product targeting at-home testing Next-Gen Ainos Flora will advance with NVIDIA CUDA, targeting Q3 for design completion and Q4 for clinical trial kickoff ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 12.4% to $0.0886 on volume of 1,366,648,994 shares Ascent Solar Technologies Inc (ASTI) rose 63.4% to $0.2147 on volume of 656,794,712 shares Pineapple Energy Inc. (PEGY) rose 61.4% to $...